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Abbreviations used:   
ALD, alcoholic liver disease; AFP, alpha-fetoprotein; -SMA, -smooth-muscle actin; AMPK, AMP-
activated protein kinase; APCs, antigen presenting cells; ASH, alcoholic steato-hepatitis; Atg, 
autophagy- related gene; bFGF, basic fibroblast growth factor; Bcl2, B-cell lymphoma/leukemia-2; 
BMP-7, bone morphogenetic protein-7;  CCl4, carbon tetrachloride;  CDAA, choline-devoid and 
aminoacid-refined;  CLD, chronic liver diseases; CK-19, cytokeratin 19; CREB, cAMP response 
element binding protein; CTGF,  connective tissue growth factor;  DAG, diacylglycerol;  DALYs, 
Disability Adjusted Life Years; DAMPS, damage-associated molecular patterns; DC, dendritic cells; 
Dhh, Desert hedgehog;  ECM, extracellular matrix; EMT, epithelial to mesenchymal transition; ER, 
endoplasmic reticulum; ERK, extracellular signal - regulated kinase; ET-1, endothelin-1; FasL, Fas 
ligand; FIP200, focal adhesion kinase family-interacting protein of 200 kD;  FSP-1, fibroblast-
specific protein 1; GFAP, glial fibrillary acidic protein; GFP; green fluorescent protein; Gli, 
glioblastoma family of transcription factors; GPCRs; G-protein coupled seven-transmembrane 
receptors; GSK-3β, glycogen synthase kinase-3β;  HCC, hepatocellular carcinoma; HBV, hepatitis B 
virus; HCV, hepatitis C virus; Hh, hedgehog; Hhip, Hh interacting proteins;  HIF, hypoxia inducible 
factor; HMGB1, high-mobility group box 1;  HPCs, hepatic progenitor cells; HNE, 4-hydroxy-2,3-
nonenal; HO-1, heme oxygenase 1; HSC, hepatic stellate cells; HSC-MFs, activated, myofibroblast-
like, hepatic stellate cells; HSPs, heat shock proteins; 5-HT, serotonin or 5 hydroxy-triptamine; 5-
HTR, serotonin receptor; HVPG, hepatic vein pressure gradient;  Ihh, indian hedgehog; IL, 
interleukin;  IL-1R1, IL-1 receptor type 1; IF/MFs, interface myofibroblasts; IFN,  interferon-; 
IRE1, inositol requiring protein 1; JNK1/2, isoforms 1 and 2 of c-Jun-NH2-kinases; LC3, light 
chain 3;  MAPK, mitogen-activated protein kinase; MCP1, monocyte chemoattractant protein 1 or 
CCL2;  MFs, myofibroblasts; MMP, metalloprotease; MET, mesenchymal to epithelial transition; 
MS, metabolic syndrome; MSC, mesenchymal stem cells;  mTOR, mammalian target of rapamycin; 
NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NF-kB, nuclear 
factor kB; NGF, nerve growth factor; NK, natural killer; NKT, natural killer T; NLR, NOD-like 
receptor;  NLRP3, NOD-like receptor family, pyrin domain containing 3; OLT, ortothopic liver 
transplantation;  PAMPs, pathogen-associated molecular patterns;  PDGF, platelet-derived growth 
factor;  PI3K, phosphatidylinositol 3-kinase;  PKC, protein kinase C; PMFs, portal myofibroblasts 
PIIINP, N-terminal peptide of procollagen type III;  PBC, primary biliary cirrhosis;   PPAR-, 
peroxisome proliferator-activated receptor-;   PRRs, pattern recognition receptors; PSC, primary 
sclerosing cholangitis; PS/MFs, portal/septal myofibroblasts; PKA, protein kinase A; Ptc, Patched; 
RA, retinoic acid; RAE1; retinoic acid inducible gene 1; ROS, reactive oxygen species; SEC, 
sinusoidal endothelial cells; SERT, specific serotonin transporter; Shh, Sonic hedgehog; Smo, 
smoothened receptor; TGFβ1, transforming growth factor β1; TGFß2, transforming growth factor 
β2;  THP2, tryptophan-hydroxylase 2;   Tie2, angiopoietin I receptor;  TIMPs, tissue inhibitor of 
metalloproteases; TLR, toll-like receptor; TNF, tumor necrosis factor ;  TNFβ, tumor necrosis 
factor β; TRAIL, TNF-related apoptosis-inducing ligand    ULC, Unc-51-like kinase; UPR, unfolded 
protein response; Vps34, vacuolar protein sorting 34; VEGF, vascular endothelial growth factor; 
VEGFR-2, VEGF receptor type 2; VHL, von Hippel-Lindau protein; XBP1, X-box binding protein 1.  
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Abstract  
Liver fibrogenesis is a dynamic and highly integrated molecular, tissue and cellular process, 
potentially reversible, that drives the progression of chronic liver diseases (CLD)  towards liver 
cirrhosis and hepatic failure.  Hepatic myofibroblasts (MFs), the pro-fibrogenic effector cells, 
originate mainly from activation of hepatic stellate cells and portal fibroblasts being characterized 
by a proliferative and survival attitude. MFs also contract in response to vasoactive agents, sustain 
angiogenesis and recruit and modulate activity of cells of innate or adaptive immunity. Chronic 
activation of wound healing and oxidative stress as well as derangement of epithelial-
mesenchymal interactions are “major” pro-fibrogenic mechanisms, whatever the etiology. 
However, literature has outlined a complex network of pro-fibrogenic factors and mediators 
proposed to modulate CLD progression, with some of them being at present highly debated in the 
field, including the role of epithelial to mesenchymal transition and Hedgehog signaling pathways. 
Hypoxia and angiogenesis as well as inflammasomes are recently emerged as ubiquitous pro-
inflammatory and pro-fibrogenic determinants whereas adipokines are mostly involved in  CLD 
related to metabolic disturbances (metabolic syndrome and/or obesity and type 2 diabetes). 
Finally, autophagy as well as natural killer and natural killer - T cells have been recently proposed 
to significantly affect fibrogenic CLD progression.   
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Liver fibrogenesis: a driving force for the progression of chronic liver diseases 
 
Definitions,  introductory remarks and the overall relevance of fibrogenesis  
Chronic liver diseases (CLD) of clinical relevance are typically characterized by persisting 
parenchymal (i.e., hepatocyte) injury that can be induced by a number of well defined etiological 
agents or conditions. On a worldwide perspective the following CLD etiologies are the most 
relevant: i) chronic infection by hepatotropic viruses (hepatitis B and C viruses only); ii) chronic 
exposure to toxins or drugs (with excess alcohol consumption being predominant in western 
countries); iii) chronic exposure to altered metabolic conditions; iv)  persisting autoimmune injury.  
Persistent liver injury can result in chronic activation of inflammatory and wound healing response 
that, in parallel or in association with other pathogenic mechanisms, including at least oxidative 
stress and the derangement of interactions between epithelial and mesenchymal cells, then 
sustain liver fibrogenesis, the process that represents a major driving force for liver fibrosis (that 
is, the net tissue result of fibrogenesis)  [1-5]. 
Accordingly, liver fibrogenesis can be defined as a dynamic and highly integrated 
molecular, tissue and cellular process that during the course of a CLD leads to a progressive excess 
accumulation of extracellular matrix (ECM) components (i.e., liver fibrosis) in an attempt to limit 
the consequences of chronic parenchymal injury [1-3]. Liver fibrogenesis, irrespective of the 
etiology, is believed to be critical for the progression of any form of chronic liver disease (CLD) and 
persisting fibrogenesis is widely recognized as the major driving force eventually leading to liver 
cirrhosis and hepatic failure [1-3,6]. Along these lines, cirrhosis is currently defined as an advanced 
stage of CLD, characterized by the formation of regenerative nodules of parenchyma surrounded 
and separated by fibrotic septa, and associated with significant changes in organ vascular 
architecture, development of portal hypertension and related complications, including variceal 
bleeding, hepatic encephalopathy, ascites and hepatorenal syndrome [1-6].  
In an attempt to describe the relevance of fibrogenesis, according to the concepts nicely 
outlined in a recent authoritative review on this specific topic [6], one may refer to a general 
scheme for CLD progression that include at least four stages which intimately related to major 
pathophysiological events.   
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The first stage, whatever the etiology, is dominated by the inter-related sequence of 
persisting chronic parenchymal injury (leading to chronic necrosis and/or apoptosis), chronic 
inflammatory response and chronic activation of fibrogenesis, which is the driving force for excess 
deposition of ECM component (i.e., fibrosis).  When trying to synthetically describe this first stage 
(see Figure 1), a number of concepts should be taken in mind [1-6]: i) perpetuation of hepatic 
injury, a typical hallmark of CLD progression, depends not only from chronic exposure to the 
specific etiology but also results from chronic injury itself and chronic inflammatory response, 
through a number of final mediators (with a prevailing role of reactive oxygen species or ROS); ii) 
chronic activation of inflammatory response and recruitment/activation of cells involved in either 
innate or acquired immunity can progressively result in what one may define pro-fibrogenic 
environment, in which synthesis and release of growth factors, cytokines, chemokines, ROS and 
other mediators will from one side impair significantly hyperplasia/regeneration of hepatic tissue 
and on the other side will favor chronic activation of wound healing and fibrogenesis; iii) the pro-
fibrogenic environment will, in turn, lead to persistent activation of MF-like cells and then 
increased deposition of ECM components which is paralleled by altered/inefficient remodeling; iv) 
emerging evidence suggests a major role for hypoxia and angiogenesis in sustaining and, likely, 
driving  fibrogenesis as well as vascular changes that become more and more relevant during CLD 
progression; v) liver fibrosis in this first stage is potentially reversible, as shown by both 
experimental and clinical studies; fibrosis reversion may depend on the removal of exposure to the 
specific etiology or to effective therapy.  
When deposition of ECM components becomes significant and fibrotic septa and strictly 
related vascular changes start to modify significantly the overall structure of liver parenchyma, 
portal hypertension and related pathophysiological events start to ensue and turn CLD progression 
into the stage of cirrhosis. Indeed, apart from the histopathological diagnosis of cirrhosis, at least 
from a clinical point of view, one should not consider cirrhosis as an end point. Rather, it has been 
suggested the need to define at least two distinct stages of cirrhosis [8]: i) a stage of compensated 
cirrhosis or cirrhosis without overt clinical manifestations, with hepatic vein pressure gradient 
(HVPG) still within a range of 5-10 mm Hg; ii) a stage of decompensated cirrhosis or cirrhosis with 
clinical manifestations (HVPG values > 10-12 mm Hg).   
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The clinical impact of fibrogenic progression  
If persistent liver fibrogenesis may be envisaged as a major driving force for the 
progression of CLD towards cirrhosis, liver failure and hepatocellular carcinoma (HCC), CLD  
fibrogenic progression has then a very significant clinical impact which is best described by the 
following facts [1,6-9]. 
1. Epidemiological data indicate that approximately 180 millions of patients worldwide are 
affected by a form of CLD, with HCV chronic infection becoming predominant in western 
countries, followed by and/or associated with chronic alcohol abuse. Chronic HBV and HCV 
infections are also predominant in Asia and Africa. 25-30 % of these patients are expected to 
progress to cirrhosis. In addition, the epidemic of obesity and diabetes will accelerate progression 
of CLDs and is itself a cause of cirrhosis in the context of evolution of non-alcoholic steatohepatitis 
(NASH).                                                                                                                              
2. According to the 2010 Global Burden of Disease study [7], more than one million deaths 
(representing approx. 2.0% of all deaths) and 31,027,000 Disability Adjusted Life Years (DALYs, that 
is 1,2% of all DALYs) were due to liver cirrhosis. Alcohol-related liver cirrhosis alone was 
responsible for 493,000 deaths and 14,544,000 DALYs.  
3. Among diseases of the gastro-intestinal tract, cirrhosis represents the most common non-
neoplastic cause of death in Europe and USA and overall represents the 7th most common cause 
of death in western countries.    
4. HCC, a very aggressive malignant cancer that represents the 5th most common cancer and the 
3rd most common cause of cancer mortality worldwide, almost invariably develops on a cirrhotic 
background, although initial reports from NASH patients are suggesting that HCC may also develop 
in a fibrotic liver [8,9]. The annual rate of HCC development in cirrhotic patients has been 
estimated to vary, depending on etiology, from 2-3% to 7-8% patients.                           
5. Epidemiologists predict a peak for end-stage CLDs and HCC in the next decade [6,7], in parallel 
with a shortage of donor organs for ortothopic liver transplantation (OLT), which is currently the 
only effective treatment option for patients with cirrhosis. 
6. Progression of a CLD towards cirrhosis has been estimated to take at least 10 – 15 years and 
sometimes to require even 30 or more years, but it may be also extremely rapid in particular 
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clinical settings, such as in children affected by biliary atresia, in patients with HCV recurrence 
after OLT, or in HCV-HIV co-infected patients [1,6-9]. CLD progression is still then difficult to 
predict although a number of clinical features have been identified that may serve as predictors 
for the development of advanced fibrosis and cirrhosis, including: male gender, age <50 years, age 
at infection (particularly for HCV chronic infection), daily alcohol intake, hepatic iron content, 
obesity and diabetes mellitus as well as individual factors (differences in immune responses vs 
infectious agents and related auto-antigens, differences in drug metabolism). 
The pattern of fibrosis: the etiology and the fibrogenic cells can make the difference  
If cirrhosis can be considered as the common result of progressive fibrogenesis it is now 
increasingly clear that the specific etiology of a CLD has a relevant impact on CLD progression. 
According to the view originally proposed in 2004 [10] and then progressively refined in recent 
years [2,6], a number of defined and distinct patterns of fibrosis development can be recognized in 
relation to the specific etiology which, in turn, can also significantly influence the prevailing pro-
fibrogenic mechanisms and the type(s) of pro-fibrogenic cells involved.  
1. Post-necrotic or bridging fibrosis. This pattern is typically observed in the liver of patients 
affected by chronic viral (HBV, HCV) infection or by an autoimmune disease. The pattern is 
characterized by the predominant formation of portal-central septa, which follows portal-central 
bridging necrosis and is associated with interface hepatitis, as well as by the formation of blind 
septa or septa connecting different portal areas. This pattern then leads to an early involvement of 
centrilobular vein, formation of neo-vessels (i.e., angiogenesis) and then porto-central shunting. 
The prevalent mechanism is here represented by chronic activation of wound healing with a 
contribution of oxidative stress, while pro-fibrogenic cells mainly originate from portal fibroblasts 
and hepatic stellate cells (HSC).  
2. Pericellular fibrosis and capillarization of sinusoids. This pattern, also defined as intercellular 
fibrosis or chicken-wire fibrosis, is observed in the liver of patients suffering of metabolic 
derangements such as those with NASH and alcoholic steato-hepatitis (ASH) as well as in patients 
with hemochromatosis. In these conditions excess deposition of ECM starts in the space of Disse 
and is mainly the results of activation of perisinusoidal hepatic stellate cells. This results in 
extensive capillarization of sinusoids which precedes formation of septal bridging and leads to a 
pattern of fibrosis development that tends to be centro-portal. The prevailing mechanism is here 
represented by oxidative stress in association to lipotoxicity.   
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3. Biliary fibrosis. This pattern of fibrosis is seen in primary and secondary biliary cirrhosis as well 
as in primary sclerosing cholangitis and is characterized by formation of portal-portal fibrotic septa 
surrounding liver nodules. This pattern of fibrosis develops by preserving connection between 
central vein and portal tract and is typically associated to intense proliferation of reactive bile 
ductules and periductular myofibroblasts that are supposed to derive mainly from portal 
fibroblasts and hepatic stellate cells. Oxidative stress and derangement of the epithelial-stromal 
equilibrium around bile ducts are believed to play a major role in sustaining fibrogenesis.  
4. Centrilobular fibrosis. This is a characteristic pattern of advanced fibrosis which is secondary to 
venous outflow obstruction (as in heart failure patients). In these conditions the fibrotic septa 
develop among central vein areas (central-central septa) leading to the unique feature defined as 
“reversed lobulation”.   
Liver fibrosis as a potentially reversible process     
In the last two decades experimental and clinical studies have provided considerable 
evidence indicating that liver fibrosis and, possibly, even cirrhosis should be considered as 
potentially reversible processes [1,3,6,11]. As outlined by several researchers in authoritative 
reviews [1,3,6,11], critical issues in fibrosis and cirrhosis reversal, providing that the etiological 
agent or condition may be eliminated or efficiently counteracted by means of selective therapy, 
are represented by the induction of hepatic MFs apoptosis and by an increased degradation of 
excess ECM. This has opened the way to experimental studies designed to characterize more 
selective therapeutic strategies to target either hepatic MFs, specific ligand-receptor interactions 
or pro-fibrogenic signaling pathways, in order to switch on or at least potentiate fibrosis reversal.   
A first relevant issue, described mainly in experimental studies and somewhat confirmed in 
clinical studies (for example in patients undergoing successful viral eradication), is that cessation 
of liver injury can result in a significant and progressive regression in the degree of liver fibrosis. As 
mentioned, the reduction in scar tissue is accompanied by evidence of apoptosis of hepatic 
myofibroblasts (MFs), with the “rise and fall” of hepatic MFs being modulated by an altered 
balance between anti-apoptotic and pro-apoptotic signals (coming from either the extracellular or 
intracellular environment). During CLD progression the feeling is that hepatic MFs may enter into a 
“survival attitude” that is likely to be the consequence of growth factor- and ROS-mediated 
activation of Nuclear-Factor kB (NF-kB) [12] and of up-regulation of anti-apoptotic protein bcl-2 
[13] in hepatic MFs. Induction of MF apoptosis is supposed to be related to activation of death 
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receptors in MFs and withdrawal of survival signals. According to this hypothesis, it has been 
shown that mature nerve growth factor (NGF) and its pro-peptide (proNGF), may act as pro-
apoptotic and survival signals, respectively; in particular, during resolution of fibrosis the cleavage 
of proNGF by MMP-7 altered the proNGF/mature NGF balance facilitating apoptosis of MFs [14].
 Apoptosis of HSC/MFs is of course followed by a decrease in collagen production and 
synthesis of tissue inhibitor of metalloproteases (TIMPs), two major features that favor 
accumulation of ECM in CLDs. In addition, resolution of liver fibrosis has been reported to be 
accompanied by a switch in the TIMP/MMP balance, with the mentioned reduction in the hepatic 
TIMP expression being associated with an increase in the hepatic metalloprotease (MMP) 
expression [1-5]. A complementary key issue in fibrosis reversal is represented by infiltration of 
the hepatic scars by bone-marrow – derived macrophages, which are rich source of MMPs that are 
critical to the successful regression in hepatic scar, with macrophages being then able to promote 
both liver fibrosis formation and fibrosis regression [1-6,11]. 
Whether clinical conditions are concerned, several studies have reported evidence 
suggesting that reversion or regression of fibrosis and cirrhosis may also occur in human patients 
affected by chronic viral infection (in those patients responding to standard anti-HCV therapy),   
alcoholic and non-alcoholic steatohepatitis as well as autoimmune hepatitis, following effective 
therapy and/or removal of etiology [11]. However, as pointed out by different Authors [6,11,15], 
no incontrovertible evidence has been reported for complete reversal of advanced cirrhosis since 
a careful analysis of these studies may lead to prudently state that just a variable degree of fibrosis 
reversion in human patients is described. As discussed by Pinzani and his colleagues [6], this may 
also be related to a substantial lack of a common language and worldwide consensus on 
definitions available to unequivocally distinguish conditions of pre-cirrhosis or compensated 
cirrhosis from true or decompensated cirrhosis, the former being able to show reversal, 
sometimes significant, the latter being mostly unable to do so. 
Cell populations in the scenario of liver fibrogenesis 
Whatever the specific etiology or the prevailing pattern of fibrosis, liver fibrogenesis in the 
scenario of chronic liver injury  can be envisaged as a process resulting from intense and persistent 
interactions (i.e. cross talk) between hepatic cell populations which results from synthesis and 
release of several mediators (growth factors, cytokines, chemokines, ROS, vasoactive agents, etc). 
Although, as detailed later, also extrahepatic cells (mainly derived from hemopoietic bone 
10 
 
marrow) may be recruited and involved in chronically damaged liver, practically any resident liver 
cell population has been reported to play a significant role in CLD fibrogenic progression [1-5]. As 
summarized in Figure 2, the persisting scenario of etiology-related parenchymal cell injury and 
death (necrotic and/or apoptotic), chronic inflammatory response and qualitative and quantitative 
alterations of ECM unavoidably involves activated inflammatory cells, mainly resident Kupffer cells 
and macrophages recruited from peripheral blood and of bone marrow origin. These 
macrophages, when activated, offer a major role in CLD progression by synthetizing and releasing 
a whole battery of established pro-fibrogenic and pro-inflammatory mediators, with platelet-
derived growth factor (PDGF), basic fibroblast growth factor (bFGF), transforming growth factor β1 
(TGFβ1), tumor necrosis factor  (TNF-α), interleukin-1 (IL-1), monocyte chemoattractant protein-
1 (MCP-1 or CCL2) and ROS representing the most efficient ones. Liver parenchymal cells (i.e., 
hepatocytes) are believed to represent a major source of ROS as well as of other oxidative-stress–
related reactive mediators or intermediates in addition to be the most significant source, in 
quantitative terms, of vascular endothelial growth factor (VEGF) during CLD progression. Less 
obvious but still relevant is the contribution from endothelial cells (damaged/activated) and 
platelets, which are indeed a significant additional source of growth factors, cytokines and other 
mediators, with endothelial cells contributing significantly to release of vasoactive agents like NO 
and entothelin-1. In any form of CLD, however, liver fibrogenesis is mainly sustained by hepatic 
MFs which represent a heterogeneous population of cells, with the vast majority of them being 
easily recognized in fibrotic or cirrhotic human liver specimens by the immune-positivity for -
smooth-muscle actin (-SMA), the most reliable in vivo marker for these cells [16]. Hepatic MFs 
are indeed major “effectors” of liver fibrogenesis which is remarkably related to their ability to 
represent  (see Figure 2) a unique and critical cellular crossroad able to integrate all incoming 
paracrine or autocrine signals released from hepatic cell population (growth factors, pro-
inflammatory cytokines, chemokines, pro-angiogenic mediators, adipokines, ROS and others).   
Hepatic myofibroblasts: origin and phenotypic responses  
Different populations of hepatic MFs have been reported to exist in liver specimens 
obtained from chronically injured liver that may be recognised according to their antigen profile 
and/or tissue localisation [16]: i) Activated, myofibroblast-like, hepatic stellate cells (HSC-MFs), 
which are SMA-positive cells found primarily in or around capillarised sinusoids of 
fibrotic/cirrhotic livers, which originate mainly from activation/transdifferentiation of hepatic 
stellate cells (HSC); ii) Portal/septal MFs (PS/MFs), which can be found in the expanded connective 
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tissue around portal tracts (portal MFs) or in the inner part of fibrotic septa (septal MFs); portal 
and septal MFs, which display an overlapping antigen repertoire, originate from portal fibroblasts 
(PFs) through a process of activation/transdifferentiation; iii) Interface MFs (IF/MFs), that are 
found at the edge between fibrotic septa and the surrounding parenchyma (i.e., where active 
fibrogenesis occurs) that are believed to likely originate from all the different cellular sources 
hypothesized in these years [1-5]. 
Apart from the tissue localization, the heterogeneous population of hepatic MFs  can then 
originate mainly from HSC or portal fibroblasts through a process of activation/trans-
differentiation. This process leads to a highly proliferative, migratory and contractile MF-like 
phenotype, able not only to synthetize excess ECM components and to remodel the matrix itself 
but also to act in order to sustain angiogenesis and/or inflammatory response as well as to 
modulate immune response. Indeed, most of actual knowledge on hepatic MFs (Figures 3 and 4) 
comes directly from studies performed on HSC/MFs but the feeling of researchers involved in the 
field is that the most relevant phenotypic responses of MF-like cells are likely to be common to 
MFs originated from portal fibroblasts and, possibly, from other sources. Accordingly, hepatic MFs, 
although to a less extent, have been also reported to originate from cells derived from bone 
marrow (mesenchymal stem cells or MSC, fibrocytes or even hemopoietic stem cells)  and 
recruited/activated in the chronically injured liver parenchyma [1-5]. Literature data also support 
the concept that at least part of pro-fibrogenic cells in CLD may originate through a process of 
epithelial to mesenchymal transition (EMT) involving either hepatocytes or cholangiocytes [17], an 
issue that is actually the subject of intense debate.   
Established Pro-fibrogenic mechanisms  
According to the original proposal by Pinzani and Rombouts [10], as refined in the following 
years [2,6,17,18] three prevailing mechanisms have been involved in liver fibrogenesis, including: i) 
chronic activation of wound healing, ii) oxidative stress and iii) derangement of epithelial-
mesenchymal interactions.  
Chronic activation of wound healing   
 Chronic activation of wound healing in CLD and of hepatic MFs, whatever the etiology, is 
believed to represent the most common and relevant mechanism sustaining hepatic fibrogenesis, 
as suggested by the following issues:         
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- the persistence of chronic liver injury (hepatocellular and cholangiocellular) resulting in a variable 
degree of necrosis and/or apoptosis;        
- the persistence of an inflammatory infiltrate mainly composed of macrophages and lymphocytes; 
- the persistent involvement of pro-fibrogenic, MF-like (i.e., -SMA-positive), ECM-producing cells 
characterized by high proliferative attitude, migration and contractility as well as by all other 
phenotypic responses summarized in Figure 3;  
- the detection of excess (i.e. quantitative) deposition and qualitative alteration in the composition 
of the ECM, the latter being associated with an impaired ability to remodel/remove fibrillar-like 
collagens and a persistent attempt to repopulate liver parenchyma (i.e., liver regeneration or 
compensatory hyperplasia).  
 Chronic activation of wound healing reaction and hepatic MFs is believed to be sustained 
by several growth factors and cytokines, chemokines, ROS and other reactive intermediates from 
oxidative stress as well as by other established and continuously emerging polypeptides.  
According to in vivo and in vitro studies several laboratories have dissected pro-fibrogenic 
receptor-mediated or receptor-independent intracellular signalingpathways elicited by these 
mediators. Polypeptide factors, in particular, include at least PDGF, TGFß1, connective tissue 
growth factor (CTGF), endothelin-1 (ET-1), MCP1 or CCL2, TNF, adipokines and pro-angiogenic 
factors (including VEGF-A and Angiopoietin I) [1-5].   
Oxidative stress 
Involvement of oxidative stress, reactive oxygen species (ROS) and other reactive 
intermediates has been unequivocally documented in most experimental models of liver 
fibrogenesis and in all human major clinical conditions of CLDs. Oxidative stress, in particular, has 
been reported to play a predominant pro-fibrogenic role in patients affected by non-alcoholic and 
alcoholic steatohepatitis (NASH and ASH patients) [1-5,18]. The following major established 
concepts should be briefly recalled.   
1.  Oxidative stress in CLDs results from either increased generation of ROS and other reactive 
intermediates, due to the specific impact of the etiology, by injured parenchymal cells (i.e., 
hepatocytes) and/or activated inflammatory cells. For example, ROS generation may follow 
altered metabolic state (like in non-alcoholic fatty liver disease or NAFLD and NASH) or ethanol 
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metabolism (ASH), with ROS being then mainly generated by mitochondrial electron transport 
chain or through the involvement of selected cytochrome P450 isoforms like CYP2E1 or other 
redox enzymes. This scenario is often paralleled in progressive CLDs by a consistent decrease in 
the efficiency of antioxidant defences.  Moreover, in conditions of severe oxidative stress ROS and 
other intermediates, like aldehydic end-product of lipid peroxidation 4-hydroxy-2,3-nonenal (HNE) 
can be released by either activated inflammatory cells or from injured hepatocytes  to significantly 
contribute to perpetuation of cell death [1-5]. 
2.  ROS, HNE and other related reactive mediators released by damaged hepatocytes or activated 
inflammatory cells have been reported to unequivocally affect/modulate the behaviour of human 
HSC/MFs and likely of other MF-like cells. Along these lines, ROS and HNE have been reported to 
up-regulate expression of critical pro-fibrogenic genes, including pro-collagen type I, TIMP-1 and  
MCP-1 (CCL2), possibly through activation of specific signal transduction pathways and 
transcription factors, including activation of JNKs, AP-1 and, only for ROS, NF-kB [1-5,18].  
Similarly, intracellular ROS generation by NADPH-oxidase in HSC/MFs has been reported to sustain 
pro-fibrogenic signaling pathways in response to pro-fibrogenic mediators, including PDGF-BB, 
angiotensin II, and the adipokine leptin [19]. Accordingly, selective inhibition or genetic 
manipulation of NADPH oxidase subunit can effectively reduce either phenotypic responses of 
HSC/MFs or fibrogenesis (reviewed in [19]).              
3. ROS, not HNE, have been reported to stimulate proliferation of HSC/MFs and ROS can also 
contribute to stimulate oriented migration of these pro-fibrogenic cells by involving activation of  
isoforms 1 and 2 of c-Jun-NH2-kinases (JNK1/2). This redox-sensitive pro-migratory action relies 
just on a significant increase of intracellular ROS, whatever their origin; HSC/MFs can migrate in 
response to i) ROS entering them from the chronically injured microenvironment, ii) ROS released 
by mitochondria following exposure to hypoxia or iii) ROS generated by NADPH-oxidase activation 
that parallels the activation of ligand-receptor interaction elicited by chemotactic polypeptide 
factors such as PDGF-BB, VEGF-A or MCP-1 [20,21].                     
4.  Experimental studies from ethanol-induced chronic injury in rodents and clinical data from 
patients affected by alcoholic liver disease (ALD), chronic HCV infection or NAFLD indicate that 
oxidative stress- mediated injury can result in the development of circulating IgG antibodies 
directed against epitopes derived from protein modified by ROS or other intermediates. Titre of 
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these antibodies correlate with disease severity and, as proposed for either ALD or NAFLD 
patients, may serve as a prognostic predictor of progression of CLD to advanced fibrosis [22].   
Derangement of epithelial/mesenchymal interactions  
This particular mechanism [2,3,6,10] is involved mainly in cholangiopathies, a group of 
progressive disorders representing a major cause of chronic cholestasis in adult and pediatric 
patients. These disorders share a common scenario characterized by cholestasis, necrotic or 
apoptotic loss of cholangiocytes, cholangiocyte proliferation and portal/periportal inflammation 
and fibrosis. These disorders are characterized at histopathological level by the so called “ductular 
reaction”, consisting in an intense proliferation of cholangiocytes that is associated with significant 
changes in the surrounding mesenchymal cells. These changes involve first portal fibroblasts in the 
portal connective tissue and then HSC when the reaction starts to invade the surrounding 
parenchyma, and are also associated with significant changes in the ECM. An intense cross-talk 
between cholangiocytes and surrounding mesenchymal cells  is believed to result in the release of 
cytokines and pro-inflammatory mediators that are responsible for the overall scenario described 
for cholangiopathies. Injured/activated cholangiocytes are considered active “cellular actors” for 
their ability to secrete several chemokines (IL-6, tumor necrosis factor β or TNFß, IL-8, MCP-1) and 
pro-fibrogenic polypeptide mediators (PDGF-BB, ET-1, CTGF, transforming growth factor  β2 or 
TGFß2). The hypothesis here is that these factors released by activated/injured cholangiocytes are 
responsible for initiation of myofibroblastic differentiation of portal fibroblasts that express all 
related receptors. Similarly to what is known to happen during HSC trans-differentiation into 
HSC/MFs, this event is believed to be followed by an autocrine perpetuation of portal MFs 
activation resulting in biliary-like fibrosis. This putative pro-fibrogenic scenario is also sustained by 
the fact that almost the same chemokines and pro-fibrogenic polypeptides can also be produced 
by infiltrating immune, inflammatory or mesenchymal cells [2,3,10]. Moreover, portal MFs are 
increasingly recognized as cells able to contribute to fibrogenic CLD progression in other clinical 
conditions of different etiology and characterized by bridging fibrosis. Indeed, what is emerging to 
be relevant is not the specific etiology but the cross-talk between damaged/activated 
cholangiocytes and portal fibroblasts and the differentiation of the latter into portal MFs, and 
indeed ductular reaction has been reported also in HCV chronic patients as well as in NASH 
patients [3]. This concept has also a relevant pathophysiological implication, as recently shown by 
a very elegant study which has identified the Notch signalling as the one governing the ability of 
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hepatic progenitor cells (HPC, which are in portal tracts at the level of Hering’s duct) to 
differentiate into either hepatocyte or cholangiocyte [23]. If the cellular targets of chronic injury 
are cholangiocytes their interaction with surrounding cells leads MFs in the area to generate 
Jagged-1 which, in turn, drives differentiation of HPC towards cholangiocyte, also contributing to 
sustain ductular reaction. If the targets of injury are predominantly represented by hepatocytes, 
macrophages or Kupffer cells release Wnt3a that switches off Notch signaling in HPC leading them 
to hepatocellular differentiation. 
 
Emerging and/or debated mechanisms in liver fibrogenesis 
In the last decade several novel mediators and mechanisms, as well as entire signaling 
pathways and systems, have been proposed to play an active and/or critical role in sustaining liver 
fibrogenesis during the progression of CLDs.  In this review we have focused the attention on a 
defined number of emerging aspects and issues rather than to attempt to describe and discuss any 
possible “mechanism” claimed to be relevant.    
Epithelial to mesenchymal transition (EMT) process and liver fibrogenesis  
Epithelial to mesenchymal transition or EMT refers to a fundamental biologic process in which 
cells of epithelial origin undergo a phenotypic and functional transition towards cells with 
mesenchymal properties. In particular, epithelial cells undergoing EMT lose their polarization and 
specialized junctional structures, undergo cytoskeleton reorganization, and to acquire 
morphological and functional features of mesenchymal-like cells, including the ability to migrate 
and to produce and secrete components of the extracellular matrix [23-24]. EMT and the related 
opposite process of MET (mesenchymal to epithelial transition) have been originally described in 
embryonic development (where cell migration and tissue remodeling have a primary role in 
regulating morphogenesis).  More recent literature data have provided evidence suggesting that 
the EMT process may also have a significant role in cancer progression and also organ fibrosis [23-
24]. In particular, EMT has been proposed to contribute to fibrosis in those chronic conditions 
characterized by  uncontrolled activation of wound-healing response and progressive fibrogenesis, 
then including also CLD. Pertinent to this review, several studies [reviewed in 17, 24], have 
proposed that pro-fibrogenic cells, in addition to the cellular sources already mentioned, may 
originate in CLD through EMT involving either cholangiocytes or hepatocytes. 
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Following homologous studies on kidney and lung fibrosis, the first liver-related experiments 
showed that hepatocytes or cholangiocytes cultured in the presence of TGF-β rapidly acquire a 
spindle-like or fibroblastoid-like morphology accompanied by canonical EMT related changes, 
including E-cadherin down-regulation and up-regulation of mesenchymal markers like vimentin, 
desmin, -SMA and the protein S100A4, the latter also termed FSP-1 (fibroblast-specific protein 
1). In the first of these studies [25] AlbCre.R26RstoplacZ double transgenic mice were used to 
investigate whether hepatocytes undergoing EMT may contribute significantly to fibrosis in the 
chronic carbon tetrachloride (CCl4) model. Authors  reported that approx. 15% of hepatic cells 
were FSP-1 positive at the time of severe fibrosis and that approx. 5% of the hepatic cells were co-
expressing either FSP-1 and albumin or FSP-1 and β-gal, then suggestive of EMT. Moreover, in the 
same study the treatment with bone morphogenetic protein-7 (BMP-7), which is known to 
antagonize TGFβ1 signaling, significantly inhibited liver fibrosis and almost abolished putative 
EMT-derived fibroblasts/MFs, a result also obtained by another laboratory using transgenic mouse 
over-expressing Smad7 in hepatocytes [26]. The latter study also reported some morphological 
evidence for “in vivo” EMT in biopsies from chronic HBV patients. 
Experimental and clinical studies also suggested involvement of EMT of cholangiocytes in biliary-
like fibrosis, with cholangiocytes under these conditions apparently co-expressing α-SMA and 
cytokeratin 19 (the latter being a marker for cholangiocytes  and hepatic progenitor cells or HPCs) 
[27].  A very close scenario was confirmed in the same model of BDL (rat and murine) by a series of 
elegant studies from the group of Anna Mae Diehl [17], the most relevant being able to describe 
an apparently clear cause-effect relationships among EMT of cholangiocytes, appearance of portal 
MFs and biliary fibrosis as well as the closely related major involvement of Hedgehog signaling 
pathway. Morphological evidence for EMT of cholangiocytes  was also described in liver biopsies 
from human patients affected by primary sclerosing cholangitis (PSC), primary biliary cirrhosis 
(PBC) or biliary atresia [17,24]. In addition, the relevance of Hedgehog and TGFβ1-Smad2/3 
signaling was reported also in human patients [17,24]. More recently, Notch signalinghas been 
also implicated in EMT and liver fibrosis based on the reported action of the  γ-secretase inhibitor 
DAPT that, by inhibiting Notch signaling, blocked an EMT-like transition in both primary mouse 
HSCs and a rat HSC cell line as well as inhibited HSC activation and attenuated CCl4-induced rat 
liver fibrosis [28,29]. Similar reports suggested the efficacy in blocking cholangiocyte EMT by using 
the same γ-secretase inhibitor or a Jagged1-neutralizing antibody [29, 30]. 
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The initial enthusiasm has been tempered by a number of very elegant studies that have 
seriously challenged the involvement of EMT of either hepatocytes or cholangiocytes as major 
pathogenic mechanism in liver fibrogenesis. In a first study Authors employed triple transgenic 
mice expressing ROSA26 stop beta-galactosidase (beta-gal), albumin Cre, and collagen alpha1(I) 
green fluorescent protein (GFP), in order to have hepatocyte-derived cells permanently labelled by 
beta-gal and type I collagen-expressing cells labelled by GFP [31]. Using this approach in either in 
vitro conditions or in vivo models of fibrosis, Authors could not find cells expressing double-
positivity for GFP and beta-gal. Moreover, all beta-gal-positive cells exhibited the typical 
morphology of hepatocytes and did not express mesenchymal markers like α-SMA, FSP-1, desmin, 
or vimentin. Even more relevant, GFP-positive areas in fibrotic livers were coincident with fibrotic 
septa but never overlapped with X-gal-positive areas, suggesting  that type I collagen-producing 
cells were not originating from hepatocytes. 
A very similar conclusion was reached in a second study from the same group [32] in which 
EMT was again investigated with Cre/LoxP system in order to map cell fate cytokeratin 19 (CK-19) 
positive cholangiocytes in CK-19(YFP) or FSP-1(YFP) transgenic mice that were then subjected to 
bile duct ligation or chronic carbon tetrachloride treatment. When the livers of fibrotic transgenic 
mice were analyzed by specific immunostaining of CK-19(YFP) cholangiocytes showed no 
expression of EMT markers such as α-SMA, desmin, or FSP-1. Moreover, cells genetically labelled 
by FSP-1(YFP) expression did not co-express neither the cholangiocyte marker CK-19 nor E-
cadherin. These results led again Authors to conclude that EMT of cholangiocytes was not 
contributing to liver fibrogenesis in these murine models. 
A third study by the group of Brenner provided compelling evidence that FSP-1 (the putative 
and widely used marker for EMT-derived fibroblasts) in either human and experimental CLDs was 
indeed not expressed by HSC or type I collagen-producing fibroblasts [33]. Moreover, FSP1-
positive cells did not express classical markers of MFs like α-SMA and desmin, and were not 
precursors of MFs in injured livers as evaluated by genetic lineage tracing experiments. 
Surprisingly, FSP1-positive cells expressed F4/80 and other markers typical of the myeloid-
monocytic lineage and the overall data indicated that  FSP1 was expressed by a subset of 
macrophages involved in CLD progression that differed from Kupffer cells. 
A fourth study challenging EMT [34] employed lineage tracing generated by crossing the alpha-
fetoprotein (AFP) Cre mouse with the ROSA26YFP stop mouse in order to trace the fate of any cell 
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ever expressing AFP. This approach led to a genetic labeling of all cholangiocytes and hepatocytes, 
because all these epithelial cells derived from AFP-expressing precursor cells. The critical result 
here was that after inducing liver fibrosis using different models, none of the resulting MFs was 
found to originate from the genetically marked epithelial (AFP+) cells. An almost identical 
conclusion was reached by a fifth study which reported that Vimentin-CreER marked MFs did not 
undergo mesenchymal to epithelial transition [35]. 
 The real involvement of EMT as a pathogenic mechanism contributing to liver fibrogenesis 
in CLDs is then more than controversial, with accumulating evidence deposing against EMT from 
either hepatocytes or cholangiocytes [31-36]. Along these lines, an excellent very recent fate 
tracing study from the laboratory of Robert Schwabe, performed using a novel Cre-transgenic 
mouse that marks 99% of hepatic stellate cells, has shown that  HSCs give rise to 82-96% of 
myofibroblasts in models of toxic, cholestatic and fatty liver disease [37]. This study unavoidably 
strongly suggests that any contribution by EMT to fibrogenesis should be considered as minor.       
This highly debated concept has been recently reviewed in an exhaustive manner by 
leading researchers in the field [38] that described evidence for and against the involvement of 
EMT in liver fibrogenesis. Authors of this review also present most recent data obtained in their 
laboratory using again very sophisticated transgenic mice; these latter results still seem to support 
a role for EMT, although they point to one even more critical and somewhat unexpected concept: 
HSCs in the liver may represent a resident population of inherently plastic cells which can be 
reprogrammed by mesenchymal to epithelial transition (MET)-EMT to replace adult liver epithelial 
cells. 
Hedgehog signaling in the fibrogenic arena 
Hedgehog (Hh) signaling pathway is known to regulate critical cellular responses including 
proliferation, apoptosis, migration, and differentiation. The Hh signaling pathway has been 
reported to play a critical role in tissue morphogenesis during fetal development. It also modulates 
wound healing responses in a number of adult tissues and organs, including the liver during 
progression of CLDs [39]. Canonical Hh signaling is initiated by the interaction of a family of ligands 
(Sonic hedgehog – Shh, Indian hedgehog – Ihh, and Desert hedgehog – Dhh) which interact with 
the Patched (Ptc) specific cell surface receptor that is expressed on the plasma membrane of 
responsive cell. These ligands can be released by several cells exposed to specific stimuli and 
relevant examples are represented by Shh ligand,  released by HSC stimulated with PDGF or leptin; 
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similarly, Shh and Ihh ligands have been reported to be released by hepatocytes undergoing 
caspase 3-dependent apoptosis induced by several triggers, including TGFβ. However, TGFβ has 
been reported to also activate the signaling in a Ptc and Smoothened (Smo) independent way 
(non-canonical pathway) by eliciting increased transcription of glioblastoma (Gli) 2 [40]. The 
signaling can be initiated via autocrine, paracrine or endocrine loops since the source of Hh ligands 
may be a Hh-responsive cells itself or a neighboring cells or even a distant cells releasing Hh 
ligands in membrane-associated particles (exosome-like).   
Ligand-receptor interaction de-represses activity of another molecule, Smoothened (Smo), 
responsible for the propagation of the signal that leads to nuclear translocation of members of 
Glioblastoma (Gli1, Gli2, Gli3) family transcription factors, that regulate the expression of a 
number of critical Gli-target genes. In the absence of Hh ligands, Ptc represses Smo and leads to 
Gli ubiquitination and subsequent proteasomal degradation. Nuclear translocation of Gli 
transcription factors is modulated by other factors [41], including insulin-like growth factor that 
inhibits protein kinase A (PKA)-dependent phosphorylation of Gli1 in Hh-responsive cells, leading 
then to inhibition of Gli phosphorylation by glycogen synthase kinase-3β  (GSK-3β) which, in turn, 
prevents its proteosomal degradation. On the other hand, Hh–related transcription factors Gli can 
regulate the transcription of pleiotropic TGFβ-target genes, such as Snail1 [42], and influence 
expression of factors that are able to modulate Wnt signaling, including Wnt5a (a Wnt pathway 
activator) and soluble frizzled receptor-1, an inhibitor of Wnt signaling [43].   
Experimental and clinical studies that have investigated the role of Hh ligands and signaling 
pathway in normal and diseased liver have pointed out a number of relevant issues. As a first 
notion, differently from developing liver, normal liver usually expresses quite low levels of Hh 
ligands but, in turn, sinusoidal cells (HSC and sinusoidal-endothelial cells or SEC) express relatively 
high levels of Hh interacting proteins or Hhip, which are known to bind Hh ligands and then to 
prevent their interactions with respective receptors. Moreover, Hh signaling pathway has been 
reported to be progressively silenced during the process of liver epithelial cell maturation, with Ptc 
expression being highly expressed in bipotent HPCs but very low in adult hepatocytes  [44]. 
By contrast, in the progression of CLD most of liver resident cell populations (hepatocytes, 
cholangiocytes, SEC, HSC/MFs and natural-killer T (NKT) cells) have been shown to produce and 
release these ligands when exposed either to cytotoxic or pro-apoptotic stress as well as to 
relevant growth factors and cytokines generated during liver fibrogenesis. Under toxic or stress 
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conditions production and release of Hh ligands increases concomitantly to repression of Hhip 
expression by activated HSC or SEC; this allows ligand-receptor interaction and activation of the 
Hh signaling pathway in Hh-responsive cells, including  NKT cells, cholangiocytes, progenitors and 
quiescent hepatic stellate cells. Increased hepatic expression of Hh ligands and their accumulation 
in chronically injured liver indeed parallels the increase in the number of Hh-responsive cells 
according to the severity of liver injury and the extent of fibrosis [39]. 
The activation in a paracrine way of Hh signaling in each of these target cells has been 
reported to contribute and/or sustain liver fibrogenesis. Indeed, several experimental studies 
(using transgenic mice and/or inhibitors of Hh signaling such as Smo antagonists) and clinical 
studies, have outlined  a number of mechanisms, summarized as follows also in relation to the 
specific target cell:  
1. Hh ligands have been reported to directly and significantly contribute to the process of HSC 
activation and trans-differentiation, helping then to drive quiescent HSC towards the activated- 
and MF-like (i.e., pro-fibrogenic) phenotype, with HSC/MFs being both a source of and a target for 
these ligands. Hh ligands, in particular, mainly sustain proliferation of these cells as well as their 
ability to synthesize and release ECM components [44,45].   
2. Hh ligands can promote cholangiocyte proliferation, favoring the so-called ductular reaction 
which is typical in cholangiopathies and in the biliary fibrosis pattern. Moreover, Hh ligands can 
also act on cholangiocytes by up-regulating their expression of chemokines like CXCL16, resulting 
in a related recruitment of subpopulations of Hh ligand producing- and Hh-responsive immune 
cells and inflammatory cells in the injured liver (e.g., NKT cells) into liver [46-48]. In particular, Hh 
ligands and activation of Hh signaling pathway can eventually stimulate NKT cells to produce other 
putative fibrogenic factors like IL-4 and IL-13 [47,48].  
3. The expansion of the cells able to respond to Hh ligands (for example HSC/MFs population) 
practically also results in an increase of those critical pro-fibrogenic factors produced in an 
autocrine-paracrine loop by these cells such as mainly PDGF and TGFβ that, in addition to their 
well-known pro-fibrogenic potential, can exacerbate Hh signaling pathway-related events by 
stimulating further production of Hh ligands [39].  
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4.  Hh ligands and Hh signaling pathway have been reported as relevant in sustaining either 
hepatocyte or cholangiocyte EMT, although this issue is still debated (see the previous section), as 
well as to promote epithelial to mesenchymal transition  in hepatic stellate cells [39]. 
5. Increased expression of Hh ligands in condition of liver injury have been reported to activate 
liver sinusoidal endothelial cells, causing them to express adhesion factors and other mediators 
that contribute to vascular remodeling, a relevant event in the progression of CLD. 
As nicely summarized in a recent review on this topic [39], the overall message, in relation 
to the potential role of Hh pathway in liver pathophysiology, is that although transient activation 
of this signaling pathway is somewhat necessary for adult livers to regenerate after an acute 
injury, the sustained increase in Hh signaling occurring in the presence of persistent injury can 
perpetuate the expansion and the pro-fibrogenic activity of critical cell types, mainly HSC/MFs.    
 
Adipokines   
Adipokines represent a group of polypeptide hormones which are expressed 
predominantly by adipocytes and also by cells of the stroma and macrophages. Interest in these 
cytokines comes from the evidence that their expression in terms of blood levels is significantly 
modulated in patients which are either obese and/or affected by metabolic alterations resulting in 
insulin-resistance [49]. In particular, obesity and insulin resistance have been shown to correlate 
with fibrogenic progression in CLDs [49,50]; moreover, accumulation of white adipose tissue or 
type 2 diabetes, as features of the so-called metabolic syndrome (MS), are considered as 
significant risk factors for the progression of NASH to cirrhosis. Along these lines, a consistent bulk 
of recent literature data indicates that different member of the adipokine family, including at least 
leptin, adiponectin, resistin and a few emerging other adipokines, can be considered as effective 
modulators of liver fibrogenesis.   
Leptin. Leptin, the best characterize adipokine, is the product of the obese (ob) gene and is mainly 
expressed by adipose tissue, although other tissues may contribute to its secretion [49]. Leptin is 
known to act by limiting food intake and, accordingly, obesity in humans has been associated with 
the absence of leptin or with a scenario of reduced leptin-mediated signaling. The pro-fibrogenic 
role of leptin has unequivocally emerged from several studies performed either in rodent models 
of fibrosis or in cultured cells. In vivo studies have established that both the absence of leptin or 
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an impairment of leptin signaling can almost abolish the development of in vivo experimental 
fibrosis [51]. The effect of leptin is direct since food restriction does not restore fibrogenesis and 
because injection of recombinant leptin has been shown to accelerate fibrogenesis.  In particular, 
leptin can indeed directly act on HSC, Kupffer cells as well as sinusoidal endothelial cells.    
HSC have been shown to express ObRb leptin receptor, the isoform that is known to display full 
signaling capabilities [52]; ObRb expression is low in quiescent HSC to become then up-regulated 
during the process of activation/trans-differentiation towards the activated, MF-like phenotype 
[53]. Moreover, leptin has been shown to up-regulate type I procollagen expression, to potentiate 
TGFβ1-mediated effects [53], to induce tissue inhibitor of metalloproteinase-1 (TIMP1) expression 
[54] as well as to stimulate HSC proliferation and survival [55], and up-regulate expression of 
chemokines (like CCL2) in a NF-kB-dependent way [52]. Although leptin may stimulate multiple 
signaling pathways, literature data suggest that its pro-fibrogenic effects are mainly NADPH 
oxidase and ROS dependent [56] and may also be mediated by  inhibition of the expression and 
activity of peroxisome proliferator-activated receptor- (PPAR-), which maintains HSC quiescence 
and reverses HSC trans-differentiation to MFs. Recently, leptin has also been shown to modulate 
liver angiogenesis being able to both exert a direct angiogenic action in vascular endothelial cells 
[57] and stimulate HSC to increase expression and release of  vascular endothelial growth factor A 
(VEGF-A), which is the most potent pro-angiogenic cytokine [52]. This is relevant because of the 
emerging evidence indicating that angiogenesis is not only a critical component of chronic wound 
healing but can indeed favor liver fibrogenesis. Finally, it has also been reported that leptin, in 
addition to stimulate increased phagocytic activity and cytokine secretion by Kupffer cells and 
macrophages [58], may act indirectly on HSC by stimulating Kupffer cells to up-regulate their 
expression of TGFβ1 [59].  
Adiponectin. Adiponectin is one of the most abundant plasma proteins and its circulating levels 
are inversely correlated with fat mass, and directly correlate with insulin sensitivity [60].  
Adiponectin act in cells expressing AdipoR1 and AdipoR2 receptors, which are predominantly 
expressed in skeletal muscle and the liver, respectively. Literature data indicate that adiponectin 
has predominantly hepato-protective and anti-fibrogenic effects in conditions of CLD [61], as 
shown in particular in the experimental model of fibrosis induced by chronic administration of CCl4 
[62]. Adiponectin has likely a protective role also in the context of  NAFLD/NASH as shown by 
experiments in which  pericellular fibrosis was found to be more severe in adiponectin-deficient 
mice (i.v., vs wild type mice) fed a high-fat diet [63]. Moreover, adiponectin has been reported to 
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delay the progression of experimental NASH towards cirrhosis and hepatocellular carcinoma [64]. 
Adiponectin has been also proposed to act as a negative modulator of inflammation [65], an 
observation that becomes relevant in the scenario of adipose tissue inflammation, which is known 
to lead to release of free fatty acids and to an altered pattern of adipokine secretion [66]. 
However, this anti-inflammatory action of adiponectin is currently debated. In any case, 
adiponectin can act directly on HSC because these cells express both types of specific receptors 
[67,68]. Adiponectin has been reported to result in a suppression of both cytokine-stimulated 
proliferation and migration [62,67], to reduce TGFβ1-dependent effects [62] and even to favor 
induction of HSC apoptosis [68]. These anti-fibrogenic effects of adiponectin are likely to be mainly 
mediated through activation of AMP-activated protein kinase (AMPK), a critical downstream 
effector of AdipoR1 [67], although a single report suggested that blocking AdipoR2 expression 
worsened the development of fibrosis in a mouse model of dietary steatohepatitis [69]. 
Resistin. The biological role of resistin in humans is still controversial [49] and seems to differ for 
several aspects from what described in rodents. Indeed, in rodents resistin is up-regulated in diet-
induced or genetic obesity [70] whereas in humans seems to have a role in sustaining 
inflammation, as shown by studies in which resistin is up-regulated in monocytes exposed to pro-
inflammatory stimuli and in conditions of experimentally induced endotoxemia [71,72]. In relation 
to liver fibrogenesis, it has been shown that resistin expression during liver injury positively 
correlates with infiltration of inflammatory cells, which may represent the principal source of 
intrahepatic resistin [73]. Indeed, resistin expression was found to co-localize with the 
inflammatory cell marker CD43 in liver specimens from patients with alcoholic hepatitis. However, 
resistin is apparently expressed only in quiescent HSCs isolated from rats, but not in activated 
HSCs isolated from either rodents or humans [73]. Human HSC, however, respond to recombinant 
resistin by up-regulating expression of CCL2 and IL-8 in a NF-kB-dependent manner [73].  
Apelin. This adipokine represent the the endogenous ligand of the orphan G protein-coupled 
receptor APJ, and is known to display a  pro-angiogenic role [74]. The interest in apelin, which is 
expressed and secreted by adipose tissue both in mice and humans [75], has been generated by a 
study reporting that its levels were markedly increased in cirrhotic liver [76].  Apelin was found to 
be highly expressed by HSCs and in the same study the use of an antagonist of the apelin receptor 
was reported to inhibit not only angiogenesis but also hepatic fibrosis.  In addition, exposure of LX-
2, a human HSC line, to recombinant apelin resulted in an increased synthesis of type I collagen as 
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well as of PDGF-β receptor  [77]. Moreover, available data on LX2 cells at present suggest that 
apelin expression can be up-regulated by angiotensin II and endothelin-1 [77] whereas expression 
of the apelin receptor APJ is positively stimulated by exposure to hypoxia and lipopolysaccharide 
[78]. 
Hypoxia and angiogenesis 
Angiogenesis can be defined as a dynamic, hypoxia-stimulated and growth factor-
dependent process that can occur in any vascularized tissue or organ resulting in the formation of 
new blood vessels from pre-existing ones in order to ensure an adequate delivery of oxygen and 
nutrients [79-80]. Although angiogenesis may be considered as beneficial for tissue growth and 
regeneration as well as for growth and repair of injured tissues, the same process is currently 
believed to also fuel inflammatory and fibro-proliferative diseases as well as malignancies in 
different organs, including chronically injured liver. Pertinent to this review, literature data 
provided in the last decade have unequivocally linked angiogenesis to liver fibrogenesis and CLDs 
progression, suggesting that angiogenesis may favor fibrogenesis [81,82]. The presence of hypoxic 
areas within liver parenchyma in the scenario of a developing CLD is the most obvious (but not the 
only one) stimulus able to switch on the transcription of pro-angiogenic genes through the action 
of hypoxia inducible factors or HIFs [79,80]. The involvement of angiogenesis in the progression of 
CLDs, a condition in which a major general mechanism is represented by chronic activation of 
wound healing, is not really surprising. In addition, the progressive increase of tissue hypoxia 
which is detected in the CLD scenario is strictly linked to the histopathological modifications of 
liver tissue in which the increased deposition of ECM components and formation of fibrotic septa, 
paralleled by vascular changes, with the time lead to an impairment of the oxygen diffusion and 
consequent up-regulation of pro-angiogenic pathways  [81,82].   
 Evidence linking hypoxia and angiogenesis to liver fibrogenesis is now overwhelming and     
major issues and considerations can be briefly summarized as follows: i) angiogenesis and 
fibrogenesis have been shown to develop in parallel in human patients, whatever the etiology, as 
well as in any experimental model of CLD, as indicated by the presence of a high number of 
endothelial cells and microvascular structures particularly in the portal tracts and, more generally, 
within fibrotic septa [81-83]; ii) experimental and clinical studies also revealed that the expression 
of VEGF, particularly VEGF-A, is usually detected in hypoxic areas of chronically injured liver, with 
fibrogenic progression being intrinsically associated with a progressive increase in hypoxic areas in 
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liver parenchyma; iii) in vivo evidence also strongly indicated that VEGF over-expression is strictly 
associated with hypoxic areas and is mostly limited to hepatocytes as well as to activated HSC/MFs 
[81,82,84]; MFs are found at close contact with HIF-2α-positive hepatocytes and then are likely to 
be affected in their behaviour by pro-angiogenic cytokines released by hypoxic hepatocytes. At the 
same time, MFs themselves are a source of VEGF-A and angiopoietin 1 and express related 
receptors (VEGFR2, Tie-2) in CLDs [83];  iv) experiments that have compared fibrogenesis 
progression in HIF-1α liver conditional knock-out mice and related wild type animals, revealed that 
hypoxia and HIF-1α expression precede fibrosis and that the liver specific silencing of HIF-1α 
resulted in a significant reduction of liver fibrosis [85]; v) experimental anti-angiogenic therapy, 
whatever the specific drug or therapeutic strategy employed, resulted in a significant inhibition of 
fibrogenic progression, being also effective in reducing inflammatory infiltrate, the number of α-
SMA positive MFs as well as the increase in portal pressure and, with some drugs, to reduce also 
formation of porto-systemic collateral vessels and splanchnic vascularization in models of portal 
hypertensive animals  or in cirrhotic animals (reviewed in [81,82,84]).  
 Experimental studies and a number of studies performed on liver specimens obtained from 
patients affected by a form of CLDs have also pointed out that hepatic MFs, in particular HSC/MFs, 
in CLDs are likely to represent a hypoxia-sensitive and cyto- and chemokine-modulated cellular 
crossroad between critical features like necro-inflammation, pathological angiogenesis and 
fibrogenesis [81,82,84]. Exhaustive literature has indeed characterized the hypoxia-related pro-
fibrogenic and pro-inflammatory role of these cells and major concepts related to the role of 
hepatic MFs in CLDs angiogenesis may be presented according to their dependence (or not) on 
hypoxia-related mechanisms.   
MFs and their pro-angiogenic role: hypoxia-related mechanisms. Hepatic MFs, in particular 
HSC/MFs, can efficiently respond to conditions of hypoxia that are progressively increasing in 
chronically injured liver during CLD progression [81,82,84]. Major concepts can be summarized as 
follows: i) HSC and HSC/MFs respond to hypoxia in a HIF-1 related way by up-regulating 
expression of VEGF, Angiopoietin 1 as well as of their related receptor VEGFR-2 and Tie2 [83,86], 
then behaving as pro-angiogenic cells; ii) HSC/MFs and, likely, all hepatic MFs (including those 
originating from bone-marrow derived mesenchymal stem cells recruited in chronically injured 
liver) [4] represent an effective target for VEGF and angiopoietin 1; in these cells VEGF can 
stimulate proliferation and increased deposition of extracellular matrix components [81,82]), as 
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well as increased migration and chemotaxis [83,87], the latter response being also significantly 
elicited in cells just exposed to hypoxia [87]. In particular, oriented migration of MFs in response to 
either hypoxia or VEGF (as other chemotactic peptides) has been described as a biphasic 
mechanism that is first switched on by ROS released by either mitochondria or through ligand-
receptor related activation of NADPH-oxidase and proceeds through redox-dependent activation 
of Ras/ERK and c-Jun-NH2-terminal kinase isoforms (JNKs). This is followed by a delayed and 
sustained phase of migration depending on HIF-1-mediated, ROS-stabilized, up-regulation of 
VEGF expression, resulting in the subsequent chemotactic action of extracellularly released VEGF 
[87]. Immunohistochemistry analysis performed on either human or rodent fibrotic/cirrhotic liver 
has showed that positive staining for both HIF-2 and heme-oxygenase 1 (HO1, a redox-related 
marker) is mainly evident in MF-like cells in developing septa and at the border of more mature 
and larger fibrotic septa suggesting that the scenario is likely to operate also in vivo [87]. The 
relevant point is that such a morphological evidence overlaps with those observed  in human and 
rat fibrotic/cirrhotic livers [83] where -SMA positive hepatic MFs expressing VEGF, Ang-1 or the 
related receptors VEGFR-2 and Tie-2, were detected at the leading edge of tiny and incomplete 
developing septa, but not in larger bridging septa. Such a distribution may reflect the existence of 
two distinct phases of the angiogenic process during CLDs [83]: a) an early phase, occurring in 
developing septa, in which fibrogenesis and angiogenesis may be driven/modulated by HSC/MFs; 
b) a later phase, occurring in larger and more mature fibrotic septa, in which pro-angiogenic 
factors and receptors are expressed only by endothelial cells, a scenario that is likely to favor the 
stabilization of the newly formed vessels. 
  A very elegant and recent study has provided further evidence for relationships between 
HIFs and hepatic fibrogenesis by employing  hepatocyte-specific von Hippel Lindau protein (VHL) 
and HIF-1 or HIF- 2 mouse mutants [88]. When mice with liver conditional disruption of VHL 
(and then with an increased expression of both HIF-1 and HIF-2) were treated for 2 weeks with 
an ethanol-containing diet, they developed increased fibrosis. Interestingly, this increase was 
prevented when simultaneous deletion of HIF-2 (but not HIF-1), was carried out, suggesting 
that HIF-2 may prevail in regulating hepatic fibrogenesis [88]. 
MFs and their pro-angiogenic role: hypoxia-independent mechanisms. Accumulating evidence 
suggests that hepatic MFs may operate their pro-angiogenic role in a hypoxia-independent 
manner by responding to a number of stimuli, including pro-fibrogenic polypeptide mediators like 
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mainly PDGF and leptin. Whether PDGF is concerned, this factor can promote an angiogenic 
phenotype of HSC that regulates HSC-driven vascular tube formation in vitro and enhanced 
coverage of sinusoids in vivo, with PDGF then contributing to the modulation of the critical role of 
HSC/MFs in the modulation of microvascular structure and function in liver parenchyma [89]. A 
pro-angiogenic action has been proposed also for leptin, which is known to exert pro-fibrogenic 
effect in the development from NAFLD to NASH [1-5]. Leptin can directly up-regulate in human 
HSC/MFs the expression of VEGF and Ang-1 as well as of monocyte-chemoattractant protein 1 
(MCP-1 or CCL2) [86]. Interestingly, leptin operated the pro-angiogenic actions by 
recruitment/stabilization of HIF-1 and nuclear translocation of HIF-1 and in vivo the specific 
leptin receptor ObR co-localized with VEGF and -SMA after induction of fibrosis in rats. More 
recently, a study performed on human HSC/MFs has revealed that leptin and PDGF-BB can directly 
up-regulate VEGF and then the pro-angiogenic role of these cells by a common mechanism 
involving both activation of the mammalian target of rapamycin (mTOR) pathway as well as 
generation of ROS via NADPH-oxidase, the latter being relevant for HIF-1 stabilization but not for 
mTOR activation [90]. 
PDGF has been shown to exert an additional pro-angiogenic mechanism, that may have a 
role in vascular remodeling in cirrhosis. An elegant study has shown that cholangiocytes and 
HSC/MFs in response to PDGF can produce and then release Hedgehog (Hh) ligands contained in 
microparticles and that this event is likely to be relevant under condition of experimental biliary 
cirrhosis (BDL model). As previously mentioned, the action of the low amount of Hh ligand 
released by rare immature ductular-type progenitors is counteracted in normal conditions  by 
expression of Hip expressed by either quiescent HSC or fenestrated SEC. However, under 
conditions of chronic liver injury HIP expression is repressed and activation of ductular-type 
progenitor cells may result in PDGF-BB up-regulation and release; this, in turn, can lead HSC/MFs 
and ductular cells to produce Hh ligands which, in addition to other actions,    may also affect SEC 
gene expression resulting in capillarization of sinusoids and in the release of  nitric oxide, then 
contributing to vascular remodeling in cirrhosis [91]. 
Autophagy and liver fibrogenesis   
Autophagy has recently emerged as an additional mechanism able to fuel fibrogenesis 
sustained by mesenchymal cells in the liver as well as in other organs [92]. Indeed, autophagy is a 
catabolic pathway, essential to maintain cellular homeostasis, designed in order to control auto-
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degradation of cellular components included in structures defined as autophagosomes. 
Autophagosome, in turn, fuse with lysosomes leading eventually to the degradation by lysosomal 
hydrolases of material within these “autolysosomes” and to the release of resultant small 
molecules back to the cytoplasm. Autophagy is a complex, evolutionary conserved, ubiquitous and 
strictly controlled pathway that under physiological conditions works at very low levels of activity 
but may be rapidly induced by several conditions of cellular stress. Formation of autophagosomes 
and regulation of autophagic machinery requires the involvement of 14 genes defined as 
autophagy-related genes (Atg) and proceeds through distinct essential steps termed induction, 
cargo recognition/selection, vesicle and autophagosome formation, fusion and breakdown [95].  
Induction. Autophagy induction is physiologically repressed by the serine/threonine protein kinase 
mTOR (mammalian target of rapamycin), which inactivates the components that are necessary to 
switch on the pathway.  Any condition (starvation and different types of cellular stress) resulting in 
inactivation/inhibition of mTOR signaling will lead to phosphorylation and activation of the 
complex between Atg13 and focal adhesion kinase family-interacting protein of 200 kD (FIP200) by 
Unc-51-like kinases 1 (ULK1) and 2 (ULK2), resulting in activation of autophagy pathway and the 
initial formation of autophagosomes with membranes that are believed to originate from plasma-
membrane, mitochondria and endoplasmic reticulum [94]. 
Cargo recognition/selection. Autophagy machinery recognizes the “cargo” to be degraded through 
the cytosolic adaptor protein P62/sequestosome 1 that binds to the microtubule-associated 
protein 1 light chain 3 (LC3) in order to deliver  the cargo for autophagic degradation [93,94].  
Autophagosome formation. It requires the involvement of class III phosphatidylinositol 3-kinase 
(PI3K) complex, which also include the PI3K vacuolar protein sorting 34 (Vps34), beclin1, Atg 14 
and p150, with beclin 1 being inactivated in normal conditions through its binding to the anti-
apoptotic protein Bcl2 (B-cell lymphoma/leukemia-2) [93,94]. The PI3K complex then recruits two 
ubiquitin-like conjugation complexes formed by several Atg proteins, one needed for 
autophagosome formation  and the second for its elongation, both involving a key player like Atg7.  
A very complex series of reactions, leads finally to the binding of these complexes to the nascent 
phagophore and then the formation of autophagosomes [93,94].     
Fusion and breakdown. In the previous step, LC3 precursor is cleaved by Atg4 and converted to 
LC3-I which, in turn is conjugated to phosphatidyl-ethanolamine by Atg7 and Atg3, forming then 
LC3-II that remains on the autophagosome membrane until its fusion with the lysosomes [96].  
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Fusion of autophagosomes with lysosomes is then followed by the degradation of the sequestered 
materials by lysosomal hydrolases [97].    
Whether fibrogenesis is specifically concerned, high levels of autophagy have been 
detected in pro-fibrogenic cells in any tissue investigated so far, including dermal and cardiac 
fibroblasts, hepatic stellate cells, mesangial cells and synovial fibroblasts [92]. Data relating 
autophagy to liver fibrogenesis first emerged independently by two different groups that showed 
evidence for an increase of autophagy in activated HSC [98,99], both suggesting that autophagy 
has a first role in the loss of perinuclear lipid droplets (containg retinyl esters) that accompanies 
trans-differentiation of quiescent HSC towards the activated phenotype. In a first study autophagy 
was detected during in vitro activation of primary mouse HSCs by investigating typical autophagy-
related markers, including LC3. Moreover, inhibition of the autophagic process using bafilomycin 
A1 resulted in a significant decreased proliferation and expression of activation markers in either 
mouse or human activated HSCs [99]. A second study went much further by describing for the first 
time in HSC isolated from murine fibrotic livers (models of liver fibrosis induced by either CCl4 or 
thioacetamide) the involvement of autophagy during the process of culture activation by analyzing 
markers like P62, LC3I and LC3II [98]. Similar findings were also described in the same study in HSC 
in human specimens from patients chronically infected by HBV. Moreover, in culture activated 
mouse HSCs the inhibition of autophagy, obtained by either employing the pharmacological 
agents such as 3-methyl-adenine and chloroquine or by specifically knocking down Atg7 or Atg5 
expression, resulted in a significant reduction of expression of critical genes involved in 
fibrogenesis and encoding for collagen 1(I), collagen 2(I), PDGF-RB, -SMA and MMP2 [98]. 
Even more convincing have been results obtained in a specifically generated transgenic mouse line 
in which expression of Atg7 was specifically attenuated in HSC within the liver by crossing 
Atg7loxP/loxP mice with mice expressing cre recombinase under the glial fibrillary acidic protein 
(GFAP) promoter (GFAP-cre mice). Using this in vivo approach Authors showed that following 
chronic liver injury induced by either CCl4 or thioacetamide  the number of HSCs was not altered 
and liver fibrosis was almost completely abolished when compared to proper control mice [98]. 
Interestingly, in this in vivo conditions the inhibition of autophagy resulted not only in the 
prevention of activation of HSC but also in the preservation of perinuclear lipid droplets (mainly 
containing retinyl esters) which are typically lost by activated HSC during the activation/trans-
differentiation process. Authors of this study, hypothesized that in HSC the metabolism of lipid 
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droplets may provide cellular energy critical for fueling catabolic pathways of cellular activation, a 
feature which indeed disappears when inhibiting autophagy in these cells.  
In a more recent study, the same research group has provided further experimental 
evidence that correlates endoplasmic reticulum (ER) stress and generation of ROS to autophagy 
and HSCs activation [100]. The involvement of ER stress was hypothesized on the basis of the 
postulate that any condition  that augments protein synthesis is likely to increase demands on the 
endoplasmic reticulum (ER) folding capacity, then potentially triggering the classic unfolded 
protein response (UPR) in order to cope with resulting ER stress. Moreover, generation of ROS is 
known to represent a common feature of hepatic fibrogenesis, and crosstalk between altered 
redox homeostasis and ER stress has been proposed [1-5,18]. By exposing cultured HSCs to ROS or 
by feeding ethanol in vivo, Authors were able to detect up-regulation of UPR and, in particular, of 
the  IRE1α–related pathway, as well as of the Nrf2 antioxidant response. Interestingly, in both 
conditions the IREα-related splicing of XBP1 mRNA was found to trigger autophagy. Moreover, 
blockade of the IRE1α pathway in HSC significantly decreased both their activation and autophagic 
activity in a p38 MAPK-dependent manner, leading to a reduced fibrogenic response.    
The overall scenario emerging from these recent findings suggests then that the activation 
of autophagy may provide the energy required for initiating and perpetuating the activated, MF-
like phenotype of HSC in the progression of CLD.   
Inflammasomes and liver fibrogenesis  
As already mentioned in previous sections, inflammatory response has a major role in 
sustaining fibrogenesis and then the progression of CLDs, whatever the etiology. In particular, 
resident cells of innate immunity, through the binding to their pattern recognition receptors 
(PRRs), can either detect pathogen-associated molecular patterns (PAMPs) as well as damage-
associated molecular patterns (DAMPs) from injured cells, the latter event leading to the so-called 
sterile inflammation [101]. Several DAMPs can be released or generated into the extracellular 
environment by dying cells or in relation to abnormal metabolism, and then trigger sterile 
inflammation, including proteins like: i) high-mobility group box 1 (HMGB1) [102], ii) heat shock 
proteins (HSPs) [103], iii) proteins of extracellular matrix generated following tissue injury (i.e., 
hyaluronan, heparin sulfate and biglycan) as modified/cleaved by enzymes released from dying 
cells or by other proteases [104,105]. Non-protein DAMPs such as ATP and uric acid (that) can be 
released or generated during cell injury and death [106]; mitochondria are a rich source of DAMPs 
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like, in addition to ATP, mitochondrial DNA, formyl peptides and cytochrome C [107] which are 
effective stimulators of inflammation. Along these lines, inflammasomes represent a group of 
protein complexes able to recognize PAMPs and DAMPs and that control activation of the 
proteolytic enzyme caspase-1, which in turn regulates maturation of the pro-inflammatory 
cytokines IL-1β  and IL-18 [108,109]. The release of IL-1β and IL-18 can result in the activation of an 
acute inflammatory response, resulting in the production of TNF-α, interferon- (IFN-) as well as 
chemotaxis of immune cells, and induction of tissue injury. In order to obtain full activation (that 
is, to obtain the effective synthesis and release of active IL-1β and IL-18) the inflammasome 
typically requires two distinct signals: i) a first priming signal usually triggered either by PAMPs 
interacting with PRRs as well as by inflammatory citokines (TNF or IL-1) interacting with the related 
receptor; the first signal is designed to activate transcription of the genes encoding pro-IL-1β, pro-
IL-18 and NLRP3 [110]; ii) the second signal can be provided by various inflammasome ligands 
(including PAMPs) through involvement/activation of cytosolic NLR (NOD-like receptor) proteins, 
particularly NLRP3, which in turn leads to activation of caspase-1 and cleavage of pro-IL-1β and 
pro-IL-18 into the active forms [111]; the second signal can be reinforced by ROS generated after 
exposure to PAMPs and DAMPs. Inflammasome can be modulated by at least two further events: 
a) it has been reported that a cross-talk exists between inflammasome and autophagy; in 
particular, autophagic suppression of ROS generation (i.e., by sequestering in autophagosomes 
defective mitochondria which may represent a source of ROS) indirectly inhibits inflammasome 
activity [112]; b) inflammasome activity is inhibited by either cell-cell interactions or secreted 
factors (for example IFN) involving lymphocytes of adaptive immunity, particularly CD4+ effector 
and memory T cells [113].  
Pertinent to this review is the emerging evidence suggesting that this theoretically acute 
inflammatory pathway seems to be critical also for sustaining fibrogenesis in several organs 
including the lung, liver, and skin [114]. Whether CLDs are concerned, recent experimental studies, 
performed by means of selective depletion of macrophages, have outlined that macrophage 
activation in liver fibrosis has at least two distinct phases: a) during fibrogenic progression of CLDs  
liver macrophages contribute to the deposition of ECM components matrix;  b) during fibrosis 
reversion macrophages contribute mainly to matrix degradation [115]. Interestingly, mice lacking 
inflammasome components have a reduced rate of fibrosis, a finding which indicates that the 
inflammasome may be critical at least in the initial phase of macrophage-related ECM deposition. 
However, it should be emphasized that the old postulate of IL-1β as a cytokine produced only by 
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activated leukocytes and dendritic cells has been challenged by recent data which unequivocally 
indicate that other cells can express inflammasome components [115], including immune cells as 
well as hepatic stellate cells and hepatocytes [116,117].  Along these lines, we know now that 
natural killer (NK) and NK-T cells, T cells with Th1, Th2, Th17 and Th22 skewing as well as dendritic 
cells (DC, particularly in NASH) have a relevant role in liver fibrosis [118], although we still miss 
clear evidence of whether inflammasome in these immune-related cells is involved in fibrogenesis.   
At present, literature data concerning the involvement of inflammasome activation in the 
progression of CLDs are available for alcoholic steatohepatitis (ASH) and non-alcoholic 
steatohepatitis (NASH).   
In alcoholic liver disease (ALD), Toll like receptors (TLRs) and mainly TLR4 have been 
reported to be involved in tissue damage as shown by employing TLR4 deficient mice [119], with a 
relevant role likely played by PAMPs since significant reduction in the bacterial load of the 
intestine resulted in a significant improvement of liver injury [120]. At present, just a single study 
has investigated specifically the role of inflammasome components in a rodent model of ethanol-
mediated liver injury [121]. In this study Authors employed mice treated with a IL-1R antagonist 
(IL-1Ra) as well as 3 mouse models deficient in regulators of IL-1β activation (Caspase-1 and the 
adaptive protein ASC) or signaling (IL-1R1) and found that IL-1β signaling was required for the 
development of alcohol-induced liver steatosis, inflammation, and injury. Moreover, the use of 
bone marrow chimeras revealed that increased levels of IL-1β were due to up-regulation of 
Caspase-1 activity and inflammasome activation in bone marrow-derived Kupffer cells rather than 
in hepatocytes. According to these findings, experimental administration of IL-1Ra, which blocked 
IL-1 signaling, resulted in a significant decrease in ethanol-induced steatosis, inflammation and 
liver injury. Although fibrosis was not directly investigated, Authors also reported additional 
positive events following IL-Ra administration including:  i) reduction of expression of TGF-β1 and 
procollagen 1α1 and of serum levels of  hyaluronic acid, TIMP-1 and N-terminal peptide of 
procollagen type III (PIIINP); ii)  an overall reduction in the progression of ethanol-mediated liver 
injury; iii) a more rapid improvement after stopping ethanol administration [121].  
Whether NASH is concerned, data are mainly coming from experimental models in which a 
major problem is represented by the low level of liver injury that can be detected and in the 
difficulty to detect then DAMPs. However, similar to what reported for ASH, also in experimental 
NASH and in human NASH patients a clear increase in LPS levels has been detected, which is likely 
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to be due to intestinal bypass [122]. Although the role of fatty acids in activating TLRs is still 
controversial, although described, interesting studies on transgenic mice have shown that the 
absence of either TLR4 or TLR9 results in a significant reduction of NASH related parameters like 
histological score, hepatocyte death (apoptosis and necrosis) and markers of fibrogenesis [123- 
125]. These studies pointed out that TLR9 seems to be relevant for significant IL-1β production 
from Kupffer cells in experimental NASH not only in relation to steatosis but also in relation to HSC 
activation and hepatocyte death. In particular, IL-1β (which is not able to induced cell death by 
itself) may lead to liver injury and hepatocyte death indirectly by sensitizing hepatocytes to more 
conventional death signals like TNF-α. [123,126].   
A relevant point in relation to the emerging pro-fibrogenic effects of inflammasome 
activation is to understand whether this is somewhat related to a direct effect on hepatic MFs and 
their precursors exposed to DAMPs or is more indirect, being caused by IL-1β  and IL-18 released 
by DAMPs-activated cells of innate immunity. The still scarce available literature data seem, at 
present, to possibly support both hypotheses. Indeed HSC express the critical inflammasome 
components and positively respond to classic DAMPs like uric acid crystals, which are known to 
activate NLRP3 inflammasome. Although uric acid crystals may represent somewhat “alien” 
DAMPs for HSC, exposure of either human or mouse HSC to these crystals results in a further 
change in morphology (more fibroblastoid phenotype) as well as in an increased expression of  
TGF-β and collagen type I, changes which do not occur in HSC  lacking the adaptive protein Asc 
[114].   
  Concerning the “indirect” pathway, indeed Kupffer cells respond to stimuli able to activate 
NLRP3 inflammasome by producing and releasing IL-1β and IL-18 [127]. The question is whether 
IL-1β, which is known to increase during experimental liver fibrosis, may be considered  as a pro-
fibrogenic cytokine. The few data available at the moment seems to suggest that this may be in 
some way true, since liver fibrosis is significantly lower in IL-1R deficient mice [124]. In wild type 
mice experimental chronic liver injury resulted in up-regulation of IL-1, MMP-9 and MMP-13 levels 
that were elevated before the onset of HSC activation and liver fibrogenesis, whereas IL-1 
receptor-deficient mice exhibited less liver damage and reduced fibrogenesis. Moreover, 
advanced fibrosis, as determined by type-I and -III collagen mRNA expression and fibrotic septa, 
was partially attenuated by the deficiency of IL-1. Authors also report that in the early phase of 
liver injury, expression of MMP-9, MMP-13 and TIMP-1 correlated nicely with IL-1 levels, with 
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MMP-9 being expressed by desmin-positive cells (i.e., HSC). Accordingly, MMP-9-deficient mice 
were partially protected from liver injury and HSC activation [127].   
Another potentially interesting experimental study related to the role of IL-1β was 
performed using the choline-devoid and aminoacid-refined (CDAA) diet in order to induce NASH in 
wild type mice and in TLR9(-/-) mice. These transgenic mice where characterized by less 
steatohepatitis and liver fibrosis than WT mice as well as by suppression of IL-1β  production by 
Kupffer cells. Of interest, IL-1β induced fibrogenic responses in HSCs, including secretion of tissue 
inhibitor of metalloproteinase-1 whereas IL-1R(-/-) mice had reduced steatohepatitis and fibrosis, 
compared with WT mice. Mice deficient in MyD88, an adaptor molecule for TLR9 and IL-1R 
signaling, also had reduced steatohepatitis and fibrosis [123].    
Natural killer and natural killer T cells in liver fibrogenesis: friends or foes ? 
 In recent years, the role of NK and NKT cells in liver fibrogenesis has received great 
attention because these cells are enriched among liver lymphocytes and are also markedly altered 
in various liver diseases of different etiology [128]. Of interest, NK cells can prevent liver fibrosis 
whereas NKT cells can either inhibit or favor excess ECM deposition. 
NK cells are lymphocytes of the innate immune system which are able to recognize and kill 
infected and tumorigenic cells, representing a lineage of lymphoid cells that, differently from T and 
B cells, do not express an antigen receptor. NK cells use an array of cell surface receptors to detect 
changes in the expression of host cell surface molecules that typically appear on either viral- 
infected, transformed or injured cells [129]. NK do not kill normal host cells because of inhibitory 
receptor molecules like killer Ig-like receptors (KIRs) and Ly-49A and CD94/NKG2 receptors that 
recognize MHC class I molecules expressed on most normal cells. By contrast, NK cells kill target 
cells through a number of stimulatory receptors (NKp46, NKp30, NKp44, NKG2D, and DNAX 
accessory molecule-1 or CD226) [128,129] able to recognize specific ligand on target cells, 
resulting in NK activation followed by cell killing  by either exocytosis of perforin- and granzyme  
granules or by using  FAS ligand, TNF-α, and TNF-related apoptosis-inducing ligands (TRAIL). 
NKT cells are instead a heterogeneous group of T lymphocytes that recognize lipid antigens 
presented by the non-classical MHC class I-like molecule CD1 [130]. Human tissues express five 
distinct isoforms of CD1, including CD1a, -b, -c, -d, and -e. Liver NKT cells are mostly CD1d-
dependent NKT defined as type I NKT cells or classical or invariant NKT (iNKT) cells because they 
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express an invariant T cell receptor α (TCR-α) chain. iNKT activation by lipid antigens such as α-
galactosylceramide is followed by release of significant levels of IFN-γ, IL-4, IL-13, TNF-α, IL-17, and 
many other cytokines as well as by production of perforin, FasL and TRAIL in order to kill target 
cells. 
Hepatic NK cells as inhibitors of fibrogenesis. NK cells are located in the hepatic sinusoids close to 
liver non-parenchymal cells and represent a unique organ-associated NK cell population, with a 
rapid turn-over and continuously substituted by bone marrow-derived cells. NK cells account  for 
approx. 30-50% of lymphocytes in human liver and their number greatly increases in pathological 
conditions (mainly related to viral infection or acute and chronic inflammation) [128]. What is 
remarkable for liver NK cells is that they can selectively kill early activated HSC but not quiescent 
or fully activated and MF-like cells, as shown by several laboratories in culture experiments (i.e., 
co-culture of HSC and NK cells) but also in animal models and, even more relevant, in human 
patients [128]. Such a selective killing is related to the fact that during the process of activation 
early activated HSCs produce retinoic acid, which upregulates the NK cell activating ligand retinoic 
acid inducible gene 1 (RAE1) expression on HSCs. RAE1 can bind to NKG2D on NK cells then leading 
to NK cell activation and HSC death through TRAIL- and NKG2Ddependent mechanisms [131]. This 
is facilitated by the fact that early activated HSC also express on their surface TRAIL receptors.  
Fully activated and MF-like cells have lost their stores of retinol and do not produce RA and RAE1, 
becoming then resistant to NK cells. In addition, activated NK cells also produce large amount of 
IFN-γ, which can induce HSC apoptosis and cell cycle arrest, as well as by enhancing NK cell killing 
of early activated HSC [131,132]. In addition, NK cells can selectively kill senescent activated HSC, 
which are cell cycle arrested cells that accumulate in fibrotic septa during chronic liver injury and 
become inefficient in ECM synthesis but able to  up-regulate expression of extracellular matrix-
degrading enzymes [133, 134]. It has been proposed that senescence-activated HSCs express 
elevated levels of NK cell-activating ligands, becoming then sensitive to NK cell killing [133]. 
NKT cells as a two-edged sword in liver fibrogenesis.  NKT cells have a more complex role in the 
pathogenesis of liver fibrosis likely because there are more types  of NKT cells, with type I and type 
II playing different and sometimes opposing functions in the liver [128]. Moreover, as nicely 
recently reviewed [128] we essentially ignore the mechanisms by which NKT cells are activated in 
vivo by endogenous ligands and cytokines, with NKT cells that, after activation, become tolerant 
and nonresponsive to subsequent stimulation. Moreover, activated NKT cells can release high 
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amount of either anti-fibrotic (e.g., IFN-γ) and pro-fibrotic (e.g., IL-4, IL-13, hedgehog ligands, and 
osteopontin) cytokines, together with many other cytokines, chemokines, and mediators that can 
differentially regulate liver fibrogenesis. The role of NKT cells has been extensively studied in 
either experimental models and in human patients which often provided contrasting or even 
opposite conceptual results. Clinical studies performed in viral hepatitis patients (HCV etiology) 
suggest that activated human HSCs can stimulate human NK cell activation which, in turn, can kill 
activated human HSCs and then inhibit liver fibrosis. Moreover, IFN-α treatment has been shown 
to increase the ability of human NK cells from HCV patients to kill activated HSCs [135,136]. 
However, the scenario may change depending on the stage of CLD progression since NKT cells 
from HCV patients without cirrhosis produce both anti-fibrotic (IFN-γ) and pro-fibrotic (IL-4 and IL-
13) cytokines, whereas NKT cells from cirrhotic HCV patients preferentially produce IL-4 and IL-13. 
The overall feeling is that NKT cells can promote liver fibrogenesis in HCV patients [137] as possibly 
also in NASH patients [138]. However, in patients affected by ALD the scenario is opposite, with 
chronic consumption ethanol reported to suppress activation of NKT cells, then facilitating 
fibrogenesis and then fibrosis. In a recent exhaustive review Gao and Radaeva [128] have 
proposed a reasonable model to interpretate these contrasting results. The hypothesis relies on 
the knowledge that NKT cells can be activated by either lipid antigens (such as α-GalCer) 
presented by CD1d on antigen presenting cells (APCs) as well as by several cytokines, including 
mainly IL-12, IL-18, IFNα and IFNβ. The critical point is that once activated NKT cells can rapidly 
produce a wide variety of anti-fibrotic and pro-fibrotic mediators that are potentially able to either 
down-modulate or to enhance liver fibrosis. The resulting effect is then related to the balance 
between these mediators and published data suggest the following concepts: i) liver fibrogenesis 
is stimulated when activated NKT cells mainly produce mediators like IL-4, IL-13, osteopontin or Hh 
ligands, with an overall meaning of potentiating activation and proliferation of HSCs; ii) liver 
fibrogenesis is inhibited when NKT cells mainly produce IFNγ, perforin or FasL, which are of course 
relevant to induce HSC apoptosis and cell cycle arrest.  
Serotonin signaling in liver fibrogenesis   
Serotonin or 5-hydroxy-triptamine (5-HT) is a very old molecule from an evolutionary point 
of view that has a role in normal wound healing in different organ and tissues but, as recently 
emerged,  in conditions of chronic injury  can  promote aberrant wound healing resulting in tissue 
fibrosis and impaired organ regeneration [139]. 5-HT in humans acts as a neurotransmitter in the 
central nervous system but it is also produced by enterochromaffin cells of the gut with a role in 
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controlling smooth muscle contraction. 5-HT once in the plasma can be taken up through a specific 
serotonin transporter (SERT) by either platelets and mast-cells, to be then released following 
activation of these cells resulting in a number of actions including mainly 
vasoconstriction/vasodilation, cardiac development and function, metabolic rate and temperature 
control [140]. 5-HT can exert its actions on target cells expressing one of the several specific 
receptors that are the products of genes encoding for G-protein coupled seven-transmembrane 
receptors (GPCRs) and classified as either 5-HT1 (1A, 1B, etc) or 5-HT2 (2A, 2B, etc) receptors, with 
an additional 5-HT3 receptor represented by a ligand-gated ion channel [141]. What makes 
serotonin able to exert a wide range of actions on different target cells is indeed related to the 
specific G protein to which 5-HT receptors are coupled. In particular, 5-HT receptors have been 
described to couple with either Gαq/11, Gαi/o or Gαs, each of which can trigger distinct 
downstream signaling events: i) Gαq coupled receptors can signal through two distinct pathways, 
one operating through diacylglycerol (DAG) and inositol phosphates, protein kinase C (PKC) 
activation and increased cytosolic Ca2+ levels, the other involving Rho activation and downstream 
signaling leading to stress fibers and focal adhesions formation, affecting cell migration and 
adhesion; ii) in neurons Gαi/o coupled receptors operates by suppressing adenylate cyclase and 
cAMP levels  [141]; iii) Gαs coupled 5-HT receptors transduce signals by activating adenylate 
cyclase and then through cAMP, protein kinase A (PKA) and cAMP response element binding 
protein (CREB) [141].    
Serotonin, as a molecule involved in normal wound healing, can either stimulate 
vasoconstriction or vasodilation depending on the specific tissue in which is released (in the liver,   
5-HT is believed to promote vasoconstriction of liver sinusoids) depending likely to the specific 5-
HT receptors which are expressed on vascular endothelial and smooth muscle cells [142].  More 
relevant, serotonin contributes apparently to leukocyte recruitment and retention at the site of 
injury and has been reported to affect behavior and function of cells of innate and adaptive 
immunity. For example, human monocytes primed by LPS through binding to TLR4 respond to  5-
HT by increasing their secretion of critical pro-inflammatory peptides, including IL-1β, IL-6, IL-8, 
IL12p40 and TNF-α [139]. In addition, 5-HT has also reported to inhibit monocyte apoptosis via the 
5-HT1 and 5-HT7 receptors allowing monocytes to remain in tissues and to promote inflammation 
[143]. Other cells like eosinophils and mast cells respond to 5-HT by migrating whereas dendritic 
cells respond by up-regulating expression of IL-6 [139,144]. The response of T lymphocytes to 5-HT 
is rather a matter of concentration with low levels of serotonin stimulating proliferation and IL-2 
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expression [144] and high levels acting as inhibitory signals [145]. Interestingly, mice which lack 
peripheral serotonin (Tph−/− mice) have been reported to be less susceptible to steatosis-induced 
hepatic inflammation, with 5-HT acting in a pro-inflammatory way by eliciting intracellular ROS 
generation in hepatocytes following 5-HT uptake and degradation, an event which is favored by IL-
1β- and TNF-α-dependent increased expression of the mentioned SERT transporter [146].   
 Whether liver parenchyma is specifically concerned, a number of recent studies have 
revealed the involvement of serotonin signaling in either regeneration (i.e., restoration of hepatic 
mass) and fibrogenesis.  By using the conventional procedure of 70% partial hepatectomy (PHX) as 
a model to induce liver regeneration it has been described that, following surgical intervention, 
serotonin is rapidly mobilized from gut and accumulates in the remnant liver, possibly delivered 
here by platelets [148], although the latter hypothesis has been recently challenged. Available 
data suggest in any case that 5-HT can sustain hepatocyte proliferation following PHX, likely by 
acting through a restrict number of receptors (5-HT1A, 2A and 2B), as also unequivocally indicated 
by the significant impairment of regeneration observed in Tph−/− mice [147,148]. Recently, it has 
proposed that cholangiocytes may represent an additional source of serotonin as resident liver 
cells, with serotonin that once released can in turn represses cholangiocyte proliferation through a 
negative feedback mechanism [149]. Interestingly, these Authors provided evidence suggesting 
that under conditions of biliary injury  a peculiar cross-talk between cholangiocytes and MFs may 
occur, with 5-HT triggering TGFβ1 production by MFs (likely portal MFs) which, in turn,  can act 
back on cholangiocytes to repress expression of tryptophan-hydroxylase 2 (TPH2, the enzyme 
generating serotonin) and enable their proliferation.  Although this latter study represents at the 
same time an indication of the pro-fibrogenic potential of serotonin, it is correct to underline that 
a more direct involvement of serotonin in fibrogenesis was first suggested by the group of Derek 
Mann early in 2006 with a paper describing that  HSC can strongly up-regulate expression of 5-
HT2A and 5-HT2B receptors during the activation/trans-differentiation process towards the 
activated and MF-like phenotype [150]. In the same study it was also reported that HSC express 
the SERT transporter and are then able to uptake, release and respond to 5-HT by means of this 
autocrine route as well as to respond to serotonin released by either platelets or cholangiocytes 
[150]. Of interest, Authors also reported that the use of 5-HT2 receptor-selective antagonists 
resulted in inhibition of HSC proliferation and in the induction of apoptosis, a relevant issue from a 
therapeutic point of view. The same group provided another interesting study that revealed a 
major role for 5-HT2B receptor on HSC-derived myofibroblasts: signaling through this receptor has 
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been described to be able to promote fibrogenesis and, at the same time, to contribute to impair 
regeneration in a diseased liver [151]. Unequivocal evidence was provided in the latter study by 
using 5-HT2B knockout mice or specific pharmacological antagonists of 5-HT2B, both procedures 
resulting in stimulation of proliferation and suppression of fibrosis in different experimental 
models of CLD. The dual function attributed to 5-HT/5-HT2B signaling is not overall surprising since 
it is likely to rely on the fact that such a pathway can trigger  ERK- and JunD dependent activation 
of TGFβ1 expression, with TGFβ1 representing both a potent suppressor of hepatocyte 
proliferation and a powerful stimulator of fibrogenic gene expression [139]. As suggested by Mann 
and Oakley in a recent review [139], at present the overall message concerning the role of 
serotonin may be synthetized as follows: i) 5-HT/5-HT2A signaling in hepatocytes is able to sustain 
proliferation (i.e., regeneration) of hepatocytes; ii) 5-HT/5-HT2B signaling in the scenario of 
fibrogenic progression of CLDs involves and activates HSC to release TGFβ1 which can both sustain 
fibrogenesis and inhibit hepatocyte proliferation.    
 
Concluding remarks 
Liver fibrogenesis is by definition,  irrespective of etiology,  a dynamic and highly integrated 
molecular, tissue and cellular process that leads to the progressive accumulation of extracellular 
matrix (ECM) components in an attempt to limit hepatic damage in a CLD. We know at present 
that progressive fibrogenesis, sustained by a heterogeneous population of MFs that may originate 
from different cells sources, has a tremendous clinical impact since it can lead to development of 
cirrhosis and related complicances, including the development of hepatocellular carcinoma, the 
most common primary liver cancer. In this review we made an attempt to introduce the reader to 
the most relevant data and concepts emerged recently from basic and clinical studies which are   
continuously unravelling molecular, cell and tissue mechanisms having a role in driving 
fibrogenesis and then CLD progression. All these studies are fundamental in order to offer putative 
new “targets” for more selective and effective therapeutic strategies to be tested with properly 
designed clinical trials.  These strategies may represent in the future realistic options for a 
changing scenario in which fibrosis and, possibly, compensated cirrhosis, may be effectively 
reverted and or at least delayed in their progression, then decreasing the need for liver 
transplantation (i.e., at present the only effective therapy for end-stage liver disease) . 
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Figure Legends.  
Figure 1.  
Progression of chronic liver diseases: tissue events.  A scheme reporting major tissue events 
involved in the fibrogenic progression of chronic liver disease is offered that links persisting liver 
injury, irrespective to the etiology, to chronic inflammation and activation of wound repair, with 
emphasis on the role of hepatic myofibroblasts in driving the disease to significant fibrosis and 
eventually to cirrhosis, liver failure and hepatocellular carcinoma.  
 
Figure 2.  
The “chronic” scenario:  a long-standing story of cross-talk between hepatic cell populations. A 
simplified scheme of the complex scenario of interactions between major hepatic cell populations 
involved in liver fibrogenesis is offered. For any cell population is also indicated a list of major 
mediators that once produced and released are able to significantly affect the behavior of 
neighbouring cells. Hypoxia is also indicated as a condition able to affect responses of hepatic cell 
populations.  
 
Figure 3.  
Origin of hepatic myofibroblasts.  The scheme recapitulates actual knowledge on the origin / cell 
source of pro-fibrogenic hepatic myofibroblasts. 
 
Figure 4.  
The fate and role of hepatic myofibroblasts.  In the scheme are summarized established or 
proposed fate and role for hepatic myofibroblasts involved in the progression of a chronic liver 
disease, irrespective of the etiology or the cellular source of MFs.   
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